At jCyte, our dedication lies in the development of an efficient stem cell therapy for retinitis pigmentosa (RP) and the swift delivery to patients. The demand is significant as there are currently no medical remedies for RP. To address this challenge, Drs. Henry Klassen and Jing Yang have devoted decades to researching the underlying mechanisms of RP and other retinal ailments in the laboratory. Their exploration led them to retinal progenitor cells (RPCs), a specific type of stem cell with the potential to mature exclusively into retinal cells. Over time, Drs. Klassen and Yang mastered the production of high-quality RPCs in large quantities. Through pre-clinical investigations, they demonstrated that these cells have the capability to rescue and even substitute diseased retinal cells.